Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 501 to 510 of 875

TitleReference numberPublishedLast updated
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590
Letermovir for preventing cytomegalovirus disease after a stem cell transplantTA591
Nusinersen for treating spinal muscular atrophyTA588
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityTA589
Bisphosphonates for treating osteoporosisTA464
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormalityTA322
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171

Results per page

  1. 10
  2. 25
  3. 50
  4. All